Background Since the use of parathyroid hormone as a treatment for osteoporosis is limited
to two years or less, the question of whether antiresorptive therapy should follow parathyroid …

BACKGROUND: Since the use of parathyroid hormone as a treatment for osteoporosis is
limited to two years or less, the question of whether antiresorptive therapy should follow …

One year ofalendronate after one year of parathyroid hormone (1-84) for osteoporosis CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …

Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years
or less, the question of whether antiresorptive therapy should follow parathyroid hormone …

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォーム …

Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years
or less, the question of whether antiresorptive therapy should follow parathyroid hormone …

Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years
or less, the question of whether antiresorptive therapy should follow parathyroid hormone …

BACKGROUND: Since the use of parathyroid hormone as a treatment for osteoporosis is
limited to two years or less, the question of whether antiresorptive therapy should follow …

Background Since the use of parathyroid hormone as a treatment for osteoporosis is limited
to two years or less, the question of whether antiresorptive therapy should follow parathyroid …

Background Since the use of parathyroid hormone as a treatment for osteoporosis is limited
to two years or less, the question of whether antiresorptive therapy should follow parathyroid …